PAVmed (PAVM) Q1 2025 earnings summary

Executive summary

• Corporate structure stabilized, positioning as a diversified life sciences company with independently financed subsidiaries and a focus on commercializing innovative medical technologies, diagnostics, digital health, and biopharma.

• Lucid Diagnostics and Veris Health are advancing toward key milestones, with Lucid nearing Medicare coverage and Veris restarting development and launching a commercial partnership with a major cancer center.

• The company deconsolidated Lucid Diagnostics in September 2024, now accounting for it as an equity method investment, and retains a significant voting interest.

• Recent developments include positive clinical and reimbursement milestones for EsoGuard, new clinical study publications, and successful capital raises at both PAVmed and Lucid.

• Exploring expansion into the biopharma sector by evaluating clinical and late preclinical stage assets.

Financial highlights

• GAAP net income attributable to common stockholders was $17.7 million, or $0.34 per diluted share, for Q1 2025, driven by a $21 million unrealized gain on the Lucid equity investment.

• Non-GAAP adjusted loss was $0.9 million, or $(0.07) per share, for Q1 2025.

• Operating expenses for Q1 2025 were approximately $5.5 million, including $1 million in stock-based compensation and $200,000 in deal expenses.

• Cash and cash equivalents stood at $2.7 million as of March 31, 2025, up from $1.2 million at year-end 2024, with stock offerings netting approximately $30.6 million and pro forma cash over $40 million.

• Revenue was less than $0.1 million in Q1 2025 for PAVmed post-deconsolidation, while Lucid reported $0.8 million in EsoGuard revenue and 3,034 tests performed.

Outlook and guidance

• Well-positioned to benefit from subsidiary success, with plans to launch a biopharma subsidiary and leverage infrastructure for further diversification.

• Management expects recurring losses and negative cash flows from operations to continue in the near term and highlights the need to raise additional capital and increase revenues from the Veris Cancer Care Platform.

• Awaiting imminent Medicare coverage decision for EsoGuard and targeting FDA filing for Veris' implantable monitor in the first half of 2026.

• Strategic partnership with Ohio State University to enroll at least 1,000 patients in the first year post-launch.

• Expecting revenue impact from concierge and employer market initiatives in the second half of the year.